RxDoctor Payments Data

Andrew McGregor, MD

Urology · Brunswick, GANPI 1952334930

Payments from drug & device makers

$5,640in general payments, 2019–2025

Across 196 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Astellas Pharma US Inc$767
  • Boston Scientific$543
  • Neotract Inc.$289
  • Coloplast$256
  • Baxter Healthcare$247
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$91516%
  • Food & beverage$4,63582%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,640 in reported general payments places this provider in the 55th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$264,700
Medicare patients
751
Services billed
4,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron189$113,520
GemtesaVibegron64$35,063
Silodosin196$8,626
Tamsulosin Hcl742$8,019
Trospium Chloride ErTrospium Chloride49$6,868
Solifenacin Succinate240$6,800
Fesoterodine Fumarate ErFesoterodine Fumarate80$5,805
Alfuzosin Hcl ErAlfuzosin Hcl336$5,048
Finasteride445$3,857
Testosterone26$3,570
Trospium Chloride60$3,273
Oxybutynin Chloride ErOxybutynin Chloride273$2,993
Estradiol35$2,262
NitrofurantoinNitrofurantoin Macrocrystal58$1,656
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst108$1,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$767$113,520189 claims
Sumitomo Pharma America, Inc.Gemtesa$173$35,06364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 369 urology providers in Georgia.

Other urology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →